Related Experiment Video
Updated: Aug 1, 2025
10:10
Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells
Published on: October 27, 2009
18.2K
[Inhibition of platelet aggregation (Update 2023)]
Thomas C Wascher1, Thomas M Stulnig2, Christoph H Saely3,4
11. Medizinische Abteilung, Hanuschkrankenhaus, Wien, Österreich.
Wiener Klinische Wochenschrift
|April 26, 2023
Summary
Patients with diabetes face high cardiovascular risks due to thrombotic complications. Antiplatelet drugs can mitigate these risks by inhibiting platelet aggregation, as recommended by the Austrian Diabetes Association.
Area of Science:
- Cardiovascular Medicine
- Endocrinology
- Pharmacology
Context:
- Diabetes mellitus accelerates atherothrombotic disease, leading to significant cardiovascular morbidity and mortality.
- Acute thrombotic events are a primary driver of cardiovascular complications in diabetic patients.
- Inhibition of platelet aggregation is a key strategy to reduce atherothrombosis risk.
Purpose:
- To provide evidence-based recommendations for the use of antiplatelet drugs in patients with diabetes.
- To outline the Austrian Diabetes Association's guidelines on antiplatelet therapy for diabetes management.
- To summarize current scientific evidence regarding antiplatelet agents in diabetic individuals.
Summary:
- This article presents recommendations from the Austrian Diabetes Association on utilizing antiplatelet drugs for patients with diabetes.
- The guidelines focus on inhibiting platelet aggregation to combat accelerated atherothrombosis and reduce cardiovascular events.
- Current scientific evidence supports the use of antiplatelet therapy in managing diabetes-related cardiovascular risks.
Impact:
- Improved clinical management of cardiovascular risk in patients with diabetes.
- Reduced incidence of cardiovascular events and mortality in the diabetic population.
- Evidence-based guidance for healthcare professionals on prescribing antiplatelet therapy for diabetic patients.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
572
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
572
01:22Formation of the Platelet Plug
6.7K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.7K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
782
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
782
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
229
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
229
01:16Clot Retraction and Fibrinolysis
6.6K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.6K
01:27Peripheral Artery Disease III: Interprofessional Care
14
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
14